Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.
Discover Ethypharm at a glance
Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.
Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.
Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!
Ethypharm to acquire Altan Pharma, entering the Spanish market and enhancing its Critical Care portfolio and R&D pipeline
On June 18th, 2021 – Ethypharm announced that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm reinforces its late-stage R&D pipeline with a novel acute treatment of migraine
On May 19, 2021 – Ethypharm announced that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. This agreement confirms Ethypharm’s commitment to patients whose daily life is altered by pain.
Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website
Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.
Linked